← All trials
NCT05185999
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 17, 2022
- Primary completion
- Jul 1, 2023
- Completion date
- Dec 1, 2023
- First posted
- Jan 11, 2022
- Last posted
- Oct 19, 2022
- Enrollment
- 10
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of Western OntarioLead sponsor
- University of Western OntarioOverall official - principal investigator
- University of Western OntarioReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.